211 related articles for article (PubMed ID: 32087468)
21. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
23. Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy.
Schmeel FC; Simon B; Sabet A; Luetkens JA; Träber F; Schmeel LC; Ezziddin S; Schild HH; Hadizadeh DR
Eur Radiol; 2017 Mar; 27(3):966-975. PubMed ID: 27271923
[TBL] [Abstract][Full Text] [Related]
24. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization.
Wallace MC; Samuelson S; Khoo T; Ooi J; Tibballs J; Ferguson J; Preen DB; Knuiman M; Garas G; MacQuillan G; Adams LA; Jeffrey GP
J Gastroenterol Hepatol; 2020 Nov; 35(11):1945-1952. PubMed ID: 32036614
[TBL] [Abstract][Full Text] [Related]
25. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
[TBL] [Abstract][Full Text] [Related]
26. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
27. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
[TBL] [Abstract][Full Text] [Related]
28. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
29. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
31. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT.
O'Connor PJ; Pasik SD; van der Bom IM; Bishay V; Radaelli A; Kim E
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):295-301. PubMed ID: 31578635
[TBL] [Abstract][Full Text] [Related]
34. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection.
Lüdemann W; Kahn J; Pustelnik D; Hardt J; Böning G; Jonczyk M; Amthauer H; Gebauer B; Hamm B; Wieners G
Eur Radiol; 2022 Jul; 32(7):4687-4698. PubMed ID: 35230518
[TBL] [Abstract][Full Text] [Related]
35. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
[TBL] [Abstract][Full Text] [Related]
36. Diffusion-weighted MRI Is Superior to PET/CT in Predicting Survival of Patients Undergoing
Barabasch A; Heinzel A; Bruners P; Kraemer NA; Kuhl CK
Radiology; 2018 Sep; 288(3):764-773. PubMed ID: 29786487
[TBL] [Abstract][Full Text] [Related]
37. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
[TBL] [Abstract][Full Text] [Related]
38. Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma.
Song Z; Ye J; Wang Y; Li Y; Wang W
J Cancer Res Ther; 2019; 15(7):1553-1560. PubMed ID: 31939437
[TBL] [Abstract][Full Text] [Related]
39. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.
Fujiwara N; Nakagawa H; Kudo Y; Tateishi R; Taguri M; Watadani T; Nakagomi R; Kondo M; Nakatsuka T; Minami T; Sato M; Uchino K; Enooku K; Kondo Y; Asaoka Y; Tanaka Y; Ohtomo K; Shiina S; Koike K
J Hepatol; 2015 Jul; 63(1):131-40. PubMed ID: 25724366
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of radioembolization for unresectable hepatocellular carcinoma in patients with marginal functional hepatic reserve.
Biederman DM; Posham R; Durrani RJ; Titano JJ; Patel RS; Tabori NE; Nowakowski FS; Fischman AM; Lookstein RA; Kim E
Clin Imaging; 2018; 47():34-40. PubMed ID: 28834778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
